Replies to post #164702 on Biotech Values

[oc631]

Right now what they have is low dose VX-135 in combination with BMS' daclatasvir and this could perhaps compete with GILD's combo in 12 weeks treatment but very unlikely a shorter one.

Are you assuming VX-135 gets back to the 200mg dose within the combination?